Focusing downstream in lung cancer prevention: 15-hydroxyprostaglandin dehydrogenase

Cancer Prev Res (Phila). 2008 Sep;1(4):223-5. doi: 10.1158/1940-6207.CAPR-08-0148.

Authors

Steven M Dubinett¹, Jenny T Mao, Saswati Hazra

Affiliation

¹ Division of Pulmonary and Critical Care Medicine, UCLA Lung Cancer Research Program, Johnsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095-1690, USA. [email protected]

PMID: 19138963
DOI: 10.1158/1940-6207.CAPR-08-0148

No abstract available

Publication types

Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung / enzymology
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / prevention & control*
Chemoprevention / methods*
Cyclooxygenase 2 / physiology
Drug Delivery Systems
Gene Expression Regulation, Enzymologic / drug effects
Gene Expression Regulation, Neoplastic / drug effects
Genes, Tumor Suppressor / physiology
Humans
Hydroxyprostaglandin Dehydrogenases / genetics*
Hydroxyprostaglandin Dehydrogenases / physiology
Lung Neoplasms / enzymology
Lung Neoplasms / prevention & control*
Signal Transduction / drug effects
Signal Transduction / genetics
Thiazolidinediones / pharmacology
Thiazolidinediones / therapeutic use

Substances

Thiazolidinediones
Hydroxyprostaglandin Dehydrogenases
15-hydroxyprostaglandin dehydrogenase
Cyclooxygenase 2
PTGS2 protein, human